Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Hematology›Condition·Updated Jul 11, 2026·v1

Warfarin

Warfarin is a vitamin K antagonist anticoagulant with a narrow therapeutic index, requiring individualized dosing and routine INR monitoring. It remains the drug of choice for mechanical heart valves and antiphospholipid syndrome. Major bleeding risk is ~3% per year, with intracranial hemorrhage being the most feared complication. Genetic polymorphisms in VKORC1, CYP2C9, and CYP4F2 explain ~50% of dose variability. Drug interactions are extensive, particularly with amiodarone, paracetamol, and carbamazepine. Time in therapeutic range (TTR) >65% is the key quality metric. DOACs are preferred for most other indications due to superior safety.

High Evidence342 references·8,916 words·36 min read·v1
warfarinanticoagulantvitamin K antagonistINRpharmacogenomicsmechanical heart valveantiphospholipid syndromebleedingdrug interaction

Quick Reference

RxDrug of choiceWarfarin for mechanical heart valves and antiphospholipid syndrome; DOACs preferred for non-valvular AF and VTE.
AltAlternativesApixaban, rivaroxaban, edoxaban, dabigatran for AF/VTE; LMWH for pregnancy and cancer.
⊘AvoidPregnancy (except mechanical valves), active bleeding, recent CNS/eye surgery, intracranial hemorrhage, cerebral aneurysm, dissecting aorta, pericarditis, bacterial endocarditis, malignant hypertension, hypersensitivity.
DxTest of choiceINR (international normalized ratio) for monitoring; consider VKORC1/CYP2C9 genotyping for dose prediction.
ScKey scoreCHA2DS2-VASc for AF stroke risk; HAS-BLED for bleeding risk; TTR for quality of anticoagulation.
→When to referMechanical heart valves, APS, recurrent thrombosis, TTR <60%, complex drug interactions, pregnancy with mechanical valves.
Warfarin is a high-risk, high-reward anticoagulant requiring meticulous monitoring; it remains irreplaceable for mechanical valves and APS, but DOACs are safer for most other indications.
Warfarin is a vitamin K antagonist anticoagulant that remains essential for mechanical heart valves and antiphospholipid syndrome despite the advent of DOACs. It requires individualized dosing based on genetics, age, and comorbidities, with routine INR monitoring to maintain a narrow therapeutic window (target INR 2.0-3.0 for most indications). Initiate at 5 mg daily (2.5-3 mg for sensitive populations), overlap with heparin for acute thrombosis, and adjust based on INR response. Major bleeding occurs at ~3% per year, with intracranial hemorrhage accounting for half; manage over-anticoagulation with vitamin K and prothrombin complex concentrate. Drug interactions are extensive, especially with amiodarone, paracetamol, and carbamazepine, requiring proactive monitoring. Time in therapeutic range (TTR) >65% is the key quality metric.

Overview and Recommendations

Key Facts

  • •Warfarin is a vitamin K antagonist that inhibits VKORC1, blocking recycling of vitamin K and thereby preventing γ-carboxylation of clotting factors II, VII, IX, X and proteins C and S, rendering them inactive. This mechanism underlies its use for VTE, AF, mechanical heart valves, and post-MI thromboembolism reduction.
  • •Despite DOACs offering fixed dosing and superior safety (lower intracranial hemorrhage and all-cause mortality), warfarin remains the only oral anticoagulant approved for mechanical heart valves and is indispensable for antiphospholipid syndrome (APS), where DOACs have shown excess thrombotic events in triple-positive patients.
  • •Warfarin has a narrow therapeutic index with dose requirements ranging from 0.5 mg to >20 mg daily, driven by genetic polymorphisms: VKORC1 -1639G>A explains ~30% of variability (AA genotype requires ~50% lower dose), CYP2C9*2/3 explains ~12%, and CYP4F2 V433M explains 5-7%. CYP2C93/*3 carriers have a 21.8-fold hazard for over-anticoagulation during initiation.
  • •The anticoagulant effect is delayed: onset within 24 hours but peak at 72-96 hours because factor II (prothrombin) has a 60-hour half-life. Early INR rise is from factor VII (half-life 4-6 hours) and does not reflect antithrombotic protection. The early drop in protein C (half-life ~8 hours) creates a transient procoagulant state, mandating heparin bridging for acute thrombosis.
  • •Warfarin's origins trace to spoiled sweet clover causing hemorrhagic disease in cattle in the 1920s; it was developed as a rodenticide before therapeutic use in 1954. Its low cost, long track record, and reversibility with vitamin K and PCC keep it relevant for patients with severe renal impairment (CrCl <15 mL/min) and in resource-limited settings.

Clinical Use

  • •Suspect need for warfarin in patients with venous thromboembolism (DVT/PE), atrial fibrillation with CHA2DS2-VASc ≥2 (men) or ≥3 (women), mechanical heart valves (especially mitral or older-generation aortic), antiphospholipid syndrome with thrombosis, or left ventricular thrombus.
  • •Assess for absolute contraindications: active bleeding, recent CNS or eye surgery, intracranial hemorrhage, cerebral aneurysm, dissecting aorta, pericarditis, bacterial endocarditis, threatened abortion, eclampsia, malignant hypertension, or hypersensitivity.
  • •Order baseline CBC, LFTs, and INR. Consider genotyping for VKORC1 and CYP2C9 to identify patients at risk for extreme dose requirements (≤21 mg/week or ≥49 mg/week).
  • •Determine target INR: 2.0-3.0 for most indications (VTE, AF, mechanical aortic valve with bileaflet and sinus rhythm); 2.5-3.5 for mechanical mitral valve, caged ball/caged disk valves, or high-risk APS.
  • •Initiate warfarin at 5 mg daily for first 1-2 days; use 2.5-3 mg in elderly (≥65 years), Asian patients, those with heart failure or hepatic impairment, or known VKORC1 AA genotype. For acute thrombosis, overlap with heparin/LMWH for ≥5 days and until INR therapeutic for 2 consecutive days.
  • •Plan bridging with LMWH for high thromboembolic risk procedures (mechanical mitral valve, recent VTE <3 months, AF with prior stroke). For low-risk patients, hold warfarin 5 days before surgery without bridging.
  • •Educate patients about consistent dietary vitamin K intake, potential drug interactions (amiodarone, paracetamol >2 g/day, antibiotics, carbamazepine, metformin), and signs of bleeding or thrombosis.
  • •Monitor INR daily/every other day during initiation until therapeutic for two consecutive measurements, then weekly, then every 2-4 weeks once stable. Aim for time in therapeutic range (TTR) >65%.
  • •Consider alternative anticoagulants: DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) are preferred for non-valvular AF and VTE due to lower intracranial hemorrhage and all-cause mortality. Reserve warfarin for mechanical valves, APS, severe renal impairment, or when DOACs are contraindicated.
  • •For cancer-associated VTE, DOACs are preferred over warfarin due to lower bleeding risk; warfarin remains an option when DOACs are contraindicated. In APS, warfarin is standard; DOACs are contraindicated due to increased thrombotic risk.

Safety

  • •Initiate warfarin at 5 mg daily for most patients; reduce to 2.5-3 mg in elderly, Asian, or VKORC1 AA carriers. Use pharmacogenetics-guided algorithms (e.g., WRAPID) to reduce over-anticoagulation risk.
  • •Titrate dose based on INR: for subtherapeutic INR (<2.0), increase dose by 10-20%; for INR 3.1-4.0, hold 1-2 doses and reduce dose by 10-20%; for INR 4.0-5.0 without bleeding, hold and consider vitamin K 1-2.5 mg oral; for INR >5.0 without bleeding, hold and give vitamin K 2.5-5 mg oral; for INR >5.0 with major bleeding, hold, give vitamin K 10 mg IV, and administer PCC (25-50 U/kg) or FFP (15 mL/kg).
  • •Monitor INR at least daily during initiation, then weekly until stable, then every 2-4 weeks. Extend to every 6-8 weeks for patients with consistently stable INRs over months. Use self-testing only in motivated patients with stable control and training.
  • •Avoid concomitant NSAIDs, antiplatelet agents (aspirin, clopidogrel, prasugrel), SSRIs, and other anticoagulants unless absolutely necessary. If combined, monitor closely for bleeding.
  • •Manage drug interactions proactively: when starting amiodarone, reduce warfarin dose by ~25% and recheck INR within one week. For paracetamol >2 g/day, anticipate INR rise and monitor within 3-5 days. For carbamazepine initiation, expect warfarin dose increase of ~50% and monitor INR weekly.
  • •Reverse warfarin for life-threatening bleeding: vitamin K 10 mg slow IV plus PCC (25-50 U/kg) or FFP (15 mL/kg). For non-major bleeding with INR >5.0, give vitamin K 2.5-5 mg oral and hold warfarin until INR <5.0.
  • •Refer patients with mechanical heart valves, APS, or recurrent thrombosis to a specialized anticoagulation clinic. Consider referral for patients with TTR <60% despite good adherence.
  • •Discharge patients with clear instructions: carry medication card, report signs of bleeding (unusual bruising, dark stools, hematuria, hematemesis), avoid new medications without consulting, maintain consistent vitamin K intake.
  • •For pregnant women with mechanical heart valves, use warfarin only if dose <5 mg daily to minimize fetal risk; otherwise, consider LMWH with anti-Xa monitoring. Warfarin is contraindicated in pregnancy for all other indications.
  • •In pediatric patients, dose based on age and body surface area; use LMWH preferentially in young children due to easier monitoring. Monitor INR frequently using pediatric-specific algorithms.
  • •For patients with APS, be aware that lupus anticoagulant may interfere with INR measurement; consider using chromogenic factor Xa assay or a PT reagent less sensitive to lupus anticoagulant for monitoring.
  • •Do not use warfarin in severe hepatic impairment (Child-Pugh C); use LMWH instead. In renal impairment (CrCl <15 mL/min), warfarin is preferred over DOACs but requires close monitoring.
  • •When restarting warfarin after a bleeding event, ensure the cause of bleeding is addressed and INR <5.0 before resuming. Consider a lower starting dose and more frequent monitoring.

Board Review — High Yield

  • •VKORC1 -1639G>A, AA genotype requires ~50% lower warfarin dose; highest frequency in East Asians (~90%).
  • •CYP2C9*3, Reduces S-warfarin clearance by ~80%; homozygous carriers have 21.8-fold hazard for over-anticoagulation.
  • •Factor II half-life 60 hours, Explains 72-96 hour delay to peak effect; early INR rise from factor VII is not antithrombotic.
  • •Protein C decline, Early drop creates transient procoagulant state; heparin bridging required for acute thrombosis.
  • •Warfarin-induced skin necrosis, Rare (<0.1%), occurs within days, associated with protein C deficiency; discontinue warfarin.
  • •Amiodarone interaction, Reduces warfarin dose requirement by ~25%; monitor INR within one week.
  • •Paracetamol >2 g/day, Causes clinically significant INR rise (mean increase 1.2); often overlooked.
  • •Anticoagulation-related nephropathy, AKI with INR >3.0 without other cause; hold warfarin and correct INR.
  • •Fiix-PT monitoring, Measures only factors II and X; reduces thromboembolism by 56% vs standard PT-INR.
  • •TTR >65%, Associated with lower thromboembolism and bleeding; TTR <60% warrants investigation.

Deep Dive — Evidence Details

References

  1. [1]

    Raskob GE, van Es N, Segers A et al.. “Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.” The Lancet. Haematology (2016). PMID: 27476789 ↗

    L1RCTCited in: Introduction and Chemical Structure, Pharmacodynamics, Indications and Clinical Use
  2. [2]

    Prins MH, Lensing AW, Brighton TA et al.. “Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.” The Lancet. Haematology (2014). PMID: 27030066 ↗

    L1RCTCited in: Introduction and Chemical Structure, Pharmacodynamics
  3. [3]

    Palumbo A, Rajkumar SV, Dimopoulos MA et al.. “Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.” Leukemia (2007). PMID: 18094721 ↗

    L5GUIDELINECited in: Introduction and Chemical Structure, Adverse Effects and Toxicity
  4. [4]

    Hijazi Z, Oldgren J, Lindbäck J et al.. “The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.” Lancet (London, England) (2016). PMID: 27056738 ↗

    L2RCTCited in: Introduction and Chemical Structure, Indications and Clinical Use
  5. [5]

    Agnelli G, Buller HR, Cohen A et al.. “Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26407753 ↗

    L1RCTCited in: Introduction and Chemical Structure
  6. [6]

    Ditkofsky N, Hanna T. “Images in Clinical Medicine. Spontaneous Retropharyngeal Hematoma.” The New England journal of medicine (2016). PMID: 26789902 ↗

    L4CASE_REPORTCited in: Introduction and Chemical Structure
  7. [7]

    Wardrop D, Keeling D. “The story of the discovery of heparin and warfarin.” British journal of haematology (2008). PMID: 18355382 ↗

    L5REVIEW_NARRATIVECited in: Introduction and Chemical Structure
  8. [8]

    Oldenburg J, Watzka M, Rost S et al.. “VKORC1: molecular target of coumarins.” Journal of thrombosis and haemostasis : JTH (2007). PMID: 17635701 ↗

    L5REVIEW_NARRATIVECited in: Introduction and Chemical Structure
  9. [9]

    Raza S, Pinkerton P, Hirsh J et al.. “The historical origins of modern international normalized ratio targets.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38795872 ↗

    L5REVIEW_NARRATIVECited in: Introduction and Chemical Structure, Monitoring and Follow-up
  10. [10]

    Gurnari C, Awada H, Pagliuca S et al.. “Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043-patient-year analysis.” Blood (2024). PMID: 38513233 ↗

    L2OTHERCited in: Introduction and Chemical Structure, Pharmacodynamics
  11. [11]

    Haque JA, McDonald MG, Kulman JD et al.. “A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites.” Blood (2013). PMID: 24297869 ↗

    L5OTHERCited in: Introduction and Chemical Structure
  12. [12]

    Czogalla KJ, Liphardt K, Höning K et al.. “VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites.” Blood advances (2018). PMID: 29581108 ↗

    L5OTHERCited in: Introduction and Chemical Structure, Pharmacodynamics, Dose and Administration, Dose Modification
  13. [13]

    Ashley EA, Butte AJ, Wheeler MT et al.. “Clinical assessment incorporating a personal genome.” Lancet (London, England) (2010). PMID: 20435227 ↗

    L4OTHERCited in: Introduction and Chemical Structure, Mechanism of Action, Resistance and Pharmacogenomics
  14. [14]

    Hijazi Z, Lindbäck J, Oldgren J et al.. “Evaluation of the updated ABC-AF-bleeding score 2.0 in patients with atrial fibrillation treated with a direct oral anticoagulant or warfarin.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41644239 ↗

    L2OTHERCited in: Introduction and Chemical Structure, Adverse Effects and Toxicity
  15. [15]

    Virk ZM, Zhang E, Rodriguez-Lopez J et al.. “Safety, tolerability, and effectiveness of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 36695393 ↗

    L2OTHERCited in: Introduction and Chemical Structure, Adverse Effects and Toxicity
  16. [16]

    de Winter MA, Uijl A, Büller HR et al.. “Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 36696208 ↗

    L2OTHERCited in: Introduction and Chemical Structure
  17. [17]

    Shen G, Li S, Cui W et al.. “Stabilization of warfarin-binding pocket of VKORC1 and VKORL1 by a peripheral region determines their different sensitivity to warfarin inhibition.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29665197 ↗

    L5OTHERCited in: Introduction and Chemical Structure, Resistance and Pharmacogenomics
  18. [18]

    Gallagher AM, Rietbrock S, Plumb J et al.. “Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18573187 ↗

    L2OTHERCited in: Introduction and Chemical Structure
  19. [19]

    Sayar Z, Speed V, Patel JP et al.. “The perils of inhibiting deficient factors.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29883037 ↗

    L4OTHERCited in: Introduction and Chemical Structure
  20. [20]

    Vlazny DT, Pasha AK, Kuczmik W et al.. “Outcome of anticoagulation in isolated distal deep vein thrombosis compared to proximal deep venous thrombosis.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34060224 ↗

    L2OTHERCited in: Introduction and Chemical Structure
  21. [21]

    Muzny CA, Lillis RA, Chavoustie SE et al.. “Refining Trichomonas vaginalis treatment in women and men: protocol for an open-label randomised comparison of multi-dose oral metronidazole versus single-dose oral secnidazole.” BMJ open (2026). PMID: 42031495 ↗

    L5TRIAL_NONRANDOMCited in: Introduction and Chemical Structure, Pharmacokinetics (LADME)
  22. [22]

    Yang W, Park HK, Koh SH et al.. “Comparison of clopidogrel-based antiplatelet therapy versus warfarin as a secondary prevention strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE): Rationale and design of a prospective, randomized, open-label, blinded-endpoint trial.” Contemporary clinical trials (2025). PMID: 41308951 ↗

    L5TRIAL_NONRANDOMCited in: Introduction and Chemical Structure
  23. [23]

    Roan JN, Hu YS, Chuang TJ et al.. “Anticoagulant adherence and associated complications and readmissions in older valve surgery adults: insights from a retrospective cohort study.” BMC geriatrics (2026). PMID: 41957737 ↗

    L2COHORTCited in: Introduction and Chemical Structure, Adverse Effects and Toxicity, Monitoring and Follow-up
  24. [24]

    Abdin B, Abuqweider E, Alhaddad I et al.. “The Effect of Multimorbidity and Anticoagulation Use in Patients with Atrial Fibrillation on The One-Year Outcome: Analysis from Jordan Atrial Fibrillation (JoFIB) Study - A Prospective Cohort Study.” BMJ open (2025). PMID: 41461398 ↗

    L2COHORTCited in: Introduction and Chemical Structure
  25. [25]

    Shukkoor AA, Turgeon RD, De Vera MA et al.. “Association of ischaemic stroke/TIA with subsequent oral anticoagulant adherence in patients with atrial fibrillation: a scoping review.” BMJ open (2026). PMID: 42331577 ↗

    L5REVIEW_NARRATIVECited in: Introduction and Chemical Structure, Monitoring and Follow-up
  26. [26]

    Alasmar R, Ibrahim R, AlHammouri H et al.. “Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Hypertrophic Cardiomyopathy: A Retrospective Cohort Study.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2026). PMID: 41838376 ↗

    L3COHORTCited in: Introduction and Chemical Structure, Adverse Effects and Toxicity
  27. [27]

    Nagai K, Mitani T, Kawahara Y et al.. “A pediatric case of anti-PF4 antibody-induced cerebral venous sinus thrombosis and thrombocytopenia following adenovirus infection: a literature review.” Brain & development (2025). PMID: 41213226 ↗

    L4CASE_REPORTCited in: Introduction and Chemical Structure
  28. [28]

    Yaman R, Arango Martinez A, Padula CA et al.. “Segmental Arterial Mediolysis and Other Mimics of Medium Vessel Vasculitis: A Case and Review.” Journal of clinical medicine (2026). PMID: 42194812 ↗

    L4CASE_REPORTCited in: Introduction and Chemical Structure
  29. [29]

    Zhang X, Liu X, Duan L et al.. “Pregnancy with treacher collins syndrome in mechanical heart valve: a case report and discussion treacher collins syndrome and MHV.” BMC pregnancy and childbirth (2026). PMID: 42032534 ↗

    L4CASE_REPORTCited in: Introduction and Chemical Structure
  30. [30]

    Mitchell S, Rojas OG, Mathavan A et al.. “A 36-Year-Old Man With Hemoptysis and Fevers.” Chest (2026). PMID: 41672657 ↗

    L4CASE_REPORTCited in: Introduction and Chemical Structure
  31. [31]

    Gong IY, Tirona RG, Schwarz UI et al.. “Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.” Blood (2011). PMID: 21725053 ↗

    L2RCTCited in: Mechanism of Action, Resistance and Pharmacogenomics, Pharmacodynamics, Dose and Administration, Dose Modification
  32. [32]

    Kimmel SE, French B, Kasner SE et al.. “A pharmacogenetic versus a clinical algorithm for warfarin dosing.” The New England journal of medicine (2013). PMID: 24251361 ↗

    L1RCTCited in: Mechanism of Action, Resistance and Pharmacogenomics
  33. [33]

    Pirmohamed M, Burnside G, Eriksson N et al.. “A randomized trial of genotype-guided dosing of warfarin.” The New England journal of medicine (2013). PMID: 24251363 ↗

    L1RCTCited in: Mechanism of Action, Resistance and Pharmacogenomics, Indications and Clinical Use
  34. [34]

    Pérez-Andreu V, Roldán V, Antón AI et al.. “Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.” Blood (2009). PMID: 19270263 ↗

    L2TRIAL_NONRANDOMCited in: Mechanism of Action, Resistance and Pharmacogenomics
  35. [35]

    Wang D, Chen H, Momary KM et al.. “Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.” Blood (2008). PMID: 18523153 ↗

    L5TRIAL_NONRANDOMCited in: Mechanism of Action, Resistance and Pharmacogenomics
  36. [36]

    Mega JL, Walker JR, Ruff CT et al.. “Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.” Lancet (London, England) (2015). PMID: 25769357 ↗

    L1RCTCited in: Mechanism of Action, Resistance and Pharmacogenomics, Indications and Clinical Use, Adverse Effects and Toxicity
  37. [37]

    Franchini M, Mengoli C, Cruciani M et al.. “Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 25040440 ↗

    L1SR_OBSCited in: Mechanism of Action, Resistance and Pharmacogenomics, Indications and Clinical Use
  38. [38]

    Kimmel SE. “Warfarin pharmacogenomics: current best evidence.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26149035 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action, Resistance and Pharmacogenomics, Adverse Effects and Toxicity, Monitoring and Follow-up
  39. [39]

    Ross S, Nejat S, Paré G. “Use of genetic data to guide therapy in arterial disease.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26149037 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action, Resistance and Pharmacogenomics, Pharmacokinetics (LADME), Pharmacodynamics
  40. [40]

    Price ET. “Warfarin pharmacogenomics and African ancestry.” Blood (2015). PMID: 26206946 ↗

    L5OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics
  41. [41]

    Limdi NA, Brown TM, Yan Q et al.. “Race influences warfarin dose changes associated with genetic factors.” Blood (2015). PMID: 26024874 ↗

    L2OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics, Pharmacodynamics, Dose and Administration, Dose Modification
  42. [42]

    Tie JK, Jin DY, Straight DL et al.. “Functional study of the vitamin K cycle in mammalian cells.” Blood (2011). PMID: 21239697 ↗

    L5OTHERCited in: Mechanism of Action
  43. [43]

    Wadelius M, Chen LY, Lindh JD et al.. “The largest prospective warfarin-treated cohort supports genetic forecasting.” Blood (2008). PMID: 18574025 ↗

    L2OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics, Pharmacodynamics, Dose and Administration, Dose Modification
  44. [44]

    Parker AL, Waddington SN, Nicol CG et al.. “Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes.” Blood (2006). PMID: 16788098 ↗

    L5OTHERCited in: Mechanism of Action
  45. [45]

    Limdi NA, Wadelius M, Cavallari L et al.. “Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.” Blood (2010). PMID: 20203262 ↗

    L2OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics, Dose and Administration, Dose Modification
  46. [46]

    Daneshjou R, Gamazon ER, Burkley B et al.. “Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.” Blood (2014). PMID: 25079360 ↗

    L3OTHERCited in: Mechanism of Action
  47. [47]

    Park IK, Giovenzana C, Hughes TL et al.. “The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development.” Blood (2008). PMID: 18840707 ↗

    L5OTHERCited in: Mechanism of Action
  48. [48]

    Cooper GM, Johnson JA, Langaee TY et al.. “A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.” Blood (2008). PMID: 18535201 ↗

    L3OTHERCited in: Mechanism of Action
  49. [49]

    Klein TE, Altman RB, Eriksson N et al.. “Estimation of the warfarin dose with clinical and pharmacogenetic data.” The New England journal of medicine (2009). PMID: 19228618 ↗

    L3OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics, Pharmacodynamics, Dose and Administration, Dose Modification, Special Populations and Contraindications
  50. [50]

    Morris SA, Alsaidi AT, Verbyla A et al.. “Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review.” Clinical pharmacology and therapeutics (2022). PMID: 36149409 ↗

    L1SR_OBSCited in: Mechanism of Action, Resistance and Pharmacogenomics
  51. [51]

    Bortman LV, Mitchell F, Naveiro S et al.. “Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation.” Journal of clinical pharmacology (2023). PMID: 36433678 ↗

    L5SR_OBSCited in: Mechanism of Action
  52. [52]

    Vear SI, Ayers GD, Van Driest SL et al.. “The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.” British journal of haematology (2014). PMID: 24601977 ↗

    L4OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics, Special Populations and Contraindications
  53. [53]

    Ndadza A, Muyambo S, Mntla P et al.. “Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34382722 ↗

    L4OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics
  54. [54]

    Lenzini PA, Grice GR, Milligan PE et al.. “Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18662264 ↗

    L2OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics
  55. [55]

    Hernandez W, Gamazon ER, Aquino-Michaels K et al.. “Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 28135054 ↗

    L4OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics
  56. [56]

    Lubitz SA, Scott SA, Rothlauf EB et al.. “Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.” Journal of thrombosis and haemostasis : JTH (2010). PMID: 20128861 ↗

    L4OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics, Dose and Administration, Dose Modification
  57. [57]

    Rieder MJ, Reiner AP, Rettie AE. “Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose.” Journal of thrombosis and haemostasis : JTH (2007). PMID: 17764537 ↗

    L4OTHERCited in: Mechanism of Action
  58. [58]

    Abohelaika S, Wynne H, Avery P et al.. “Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26010205 ↗

    L2OTHERCited in: Mechanism of Action
  59. [59]

    Waizenegger JS, Ben-Batalla I, Weinhold N et al.. “Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.” Leukemia (2014). PMID: 25102945 ↗

    L5OTHERCited in: Mechanism of Action
  60. [60]

    Anand A, Hegde NC, Chhabra P et al.. “Pharmacogenetic guided versus standard warfarin dosing for routine clinical care with its pharmacoeconomic impact: a randomized controlled clinical trial.” Annals of hematology (2024). PMID: 38634917 ↗

    L1RCTCited in: Mechanism of Action, Resistance and Pharmacogenomics
  61. [61]

    Jannati S, Patnaik R, Banerjee Y. “Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling.” International journal of molecular sciences (2024). PMID: 39201414 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action
  62. [62]

    Zubiaur P, Rodríguez-Antona C, Boone EC et al.. “PharmVar GeneFocus: CYP4F2.” Clinical pharmacology and therapeutics (2024). PMID: 39135485 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action, Resistance and Pharmacogenomics
  63. [63]

    Ingelman-Sundberg M, Pirmohamed M. “Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment.” Journal of internal medicine (2024). PMID: 38343077 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action, Resistance and Pharmacogenomics
  64. [64]

    Ross S, Krebs K, Paré G et al.. “Pharmacogenomics in Stroke and Cardiovascular Disease: State of the Art.” Stroke (2022). PMID: 36325912 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action, Resistance and Pharmacogenomics
  65. [65]

    Thompson LE, Davis BH, Narayan R et al.. “Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics.” Clinical pharmacology and therapeutics (2022). PMID: 35857814 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action
  66. [66]

    Svyatova G, Berezina G, Murtazaliyeva A et al.. “GENETIC ASPECTS OF WARFARIN DOSING ALGORITHMS IN CARDIAC SURGERY PATIENTS WHO HAVE UNDERGONE HEART SURGERY: SYSTEMATIC REVIEW.” Georgian medical news (2025). PMID: 40884373 ↗

    L2SR_OBSCited in: Mechanism of Action
  67. [67]

    Ranasinghe P, Jeyapragasam H, Liyanage S et al.. “Pharmacogenomics in Sri Lanka: a comprehensive systematic review of the research landscape and clinical implications.” Pharmacogenomics (2024). PMID: 39540556 ↗

    L2SR_OBSCited in: Mechanism of Action
  68. [68]

    Shi K, Deng J. “Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation.” Pharmacogenetics and genomics (2024). PMID: 39356590 ↗

    L5TRIAL_NONRANDOMCited in: Mechanism of Action, Resistance and Pharmacogenomics, Dose Modification
  69. [69]

    Wong HJ, Teo YN, Teo YH et al.. “Subgroup analysis of genotype guided vs traditional warfarin dosing in Asian patients from an open label randomized trial.” Scientific reports (2026). PMID: 41484425 ↗

    L1RCTCited in: Mechanism of Action
  70. [70]

    Shamohammadi M, Nazari MA, Mirkalaie SMM et al.. “Artificial intelligence and machine learning for precision warfarin dosing: a comprehensive narrative review.” European journal of clinical pharmacology (2026). PMID: 41649565 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action
  71. [71]

    Spahn C, Walker T, Byurat S et al.. “The Use of Pharmacogenomics in Cardiovascular Care.” The Nursing clinics of North America (2025). PMID: 40345762 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action
  72. [72]

    Cohen H, Sayar Z, Efthymiou M et al.. “Management of anticoagulant-refractory thrombotic antiphospholipid syndrome.” The Lancet. Haematology (2020). PMID: 32735839 ↗

    L5REVIEW_NARRATIVECited in: Resistance and Pharmacogenomics
  73. [73]

    Czogalla KJ, Biswas A, Wendeln AC et al.. “Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces.” Blood (2013). PMID: 23982176 ↗

    L5OTHERCited in: Resistance and Pharmacogenomics
  74. [74]

    Chen X, Jin DY, Stafford DW et al.. “Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu.” Blood (2018). PMID: 30089628 ↗

    L5OTHERCited in: Resistance and Pharmacogenomics, Pharmacodynamics
  75. [75]

    Loebstein R, Dvoskin I, Halkin H et al.. “A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.” Blood (2006). PMID: 17110455 ↗

    L3OTHERCited in: Resistance and Pharmacogenomics, Pharmacodynamics, Dose and Administration, Dose Modification
  76. [76]

    Harrington DJ, Gorska R, Wheeler R et al.. “Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1.” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18680536 ↗

    L4OTHERCited in: Resistance and Pharmacogenomics, Pharmacokinetics (LADME)
  77. [77]

    Tie JK, Jin DY, Tie K et al.. “Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells.” Journal of thrombosis and haemostasis : JTH (2013). PMID: 23710884 ↗

    L5OTHERCited in: Resistance and Pharmacogenomics
  78. [78]

    Sabry S, El Wakeel LM, Saleh A et al.. “Comparison of Warfarin Initiation at 3 mg Versus 5 mg for Anticoagulation of Patients with Mechanical Mitral Valve Replacement Surgery: A Prospective Randomized Trial.” Clinical drug investigation (2022). PMID: 35274222 ↗

    L1RCTCited in: Resistance and Pharmacogenomics
  79. [79]

    Marathe SP, Van Dyk S, Campbell S et al.. “Platelet responsiveness to aspirin in pediatric patients undergoing cardiac surgery: A prospective cohort study.” The Journal of thoracic and cardiovascular surgery (2025). PMID: 40975432 ↗

    L2COHORTCited in: Resistance and Pharmacogenomics, Dose Modification, Special Populations and Contraindications
  80. [80]

    Lee KJ, Kang M, Lee EJ et al.. “Clinical Application of Pharmacogenomics in Stroke Management: Current Evidence and Future Directions.” Journal of stroke (2026). PMID: 41656635 ↗

    L5REVIEW_NARRATIVECited in: Resistance and Pharmacogenomics
  81. [81]

    Salem M, El-Bardissy A, Elshafei MN et al.. “Warfarin-Rifampin-Gene (WARIF-G) Interaction: A Retrospective, Genetic, Case-Control Study.” Clinical pharmacology and therapeutics (2023). PMID: 36789833 ↗

    L3CASE_CONTROLCited in: Resistance and Pharmacogenomics
  82. [82]

    Kim B, Song J, Kang J et al.. “A first-in-human study assessing the safety, pharmacokinetics, and pharmacodynamics of TU7710, a recombinant factor VIIa-transferrin fusion protein, in warfarin-pretreated healthy male participants.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41651288 ↗

    L4RCTCited in: Pharmacokinetics (LADME), Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  83. [83]

    Spyropoulos AC, Douketis JD. “How I treat anticoagulated patients undergoing an elective procedure or surgery.” Blood (2012). PMID: 22932800 ↗

    L5CASE_REPORTCited in: Pharmacokinetics (LADME)
  84. [84]

    Nakamura M, Wang YQ, Wang C et al.. “Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26179767 ↗

    L2RCTCited in: Pharmacokinetics (LADME), Pharmacodynamics
  85. [85]

    Schulman S, Crowther MA. “How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.” Blood (2012). PMID: 22302737 ↗

    L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME), Drug Interactions
  86. [86]

    Schulman S, Furie B. “How I treat poisoning with vitamin K antagonists.” Blood (2014). PMID: 25377783 ↗

    L5CASE_REPORTCited in: Pharmacokinetics (LADME), Adverse Effects and Toxicity
  87. [87]

    Lopes RD, Horowitz JD, Garcia DA et al.. “Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility.” Blood (2011). PMID: 21911832 ↗

    L4CASE_REPORTCited in: Pharmacokinetics (LADME), Adverse Effects and Toxicity, Drug Interactions, Monitoring and Follow-up
  88. [88]

    Bauer KA. “Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.” Journal of thrombosis and haemostasis : JTH (2011). PMID: 21781237 ↗

    L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME), Monitoring and Follow-up
  89. [89]

    He X, Liu G, Chen X et al.. “Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects.” Clinical therapeutics (2023). PMID: 37451912 ↗

    L4TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME), Dose Modification, Drug Interactions
  90. [90]

    Pooler DB, Ness DB, Sarantopoulos J et al.. “The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.” British journal of clinical pharmacology (2020). PMID: 32736411 ↗

    L4TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME)
  91. [91]

    Zhu Y, Xu Y, Zhuang Y et al.. “Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.” Clinical and translational science (2020). PMID: 32407591 ↗

    L4TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME)
  92. [92]

    Pinquier JL, Varastet M, Meyers D et al.. “A Colon-Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects.” Clinical pharmacology in drug development (2021). PMID: 33434399 ↗

    L1RCTCited in: Pharmacokinetics (LADME)
  93. [93]

    Alodat L, Shahin W, Breik L et al.. “Stability of Medications Administered via Enteral Feeding Tubes: A Systematic Review.” Clinical and translational science (2026). PMID: 41443608 ↗

    L5SR_OBSCited in: Pharmacokinetics (LADME)
  94. [94]

    Khalid A, Khalid A, Waite S et al.. “Exploring the use of electroconvulsive therapy in the anticoagulated population: A systematic review.” The Australian and New Zealand journal of psychiatry (2024). PMID: 39252452 ↗

    L2SR_OBSCited in: Pharmacokinetics (LADME)
  95. [95]

    Ishiguchi H, Chen Y, Huang B et al.. “Machine learning for stroke in heart failure with reduced ejection fraction but without atrial fibrillation: A post-hoc analysis of the WARCEF trial.” European journal of clinical investigation (2024). PMID: 39552607 ↗

    L2RCTCited in: Pharmacokinetics (LADME)
  96. [96]

    Desch M, Schlecker C, Hohl K et al.. “Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.” Journal of clinical psychopharmacology (2023). PMID: 36700734 ↗

    L4TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME), Drug Interactions
  97. [97]

    Ramírez J, House LK, Karrison TG et al.. “Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.” Journal of clinical pharmacology (2019). PMID: 31274208 ↗

    L4TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME)
  98. [98]

    Maagdenberg H, Bierings MB, van Ommen CH et al.. “The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29935043 ↗

    L2OTHERCited in: Pharmacokinetics (LADME), Dose and Administration, Dose Modification, Special Populations and Contraindications
  99. [99]

    Rupin A, Marx I, Vallez MO et al.. “S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.” Journal of thrombosis and haemostasis : JTH (2011). PMID: 21481181 ↗

    L5OTHERCited in: Pharmacokinetics (LADME)
  100. [100]

    Hu C, Chen X, Zhao Z et al.. “A Two-Sequence, Four-Period, Crossover, Replicate Study to Demonstrate Bioequivalence of Warfarin Sodium Tablet in Healthy Chinese Subjects Under Fasting and Fed Conditions.” Clinical pharmacology in drug development (2020). PMID: 32052925 ↗

    L1RCTCited in: Pharmacokinetics (LADME)
  101. [101]

    Gomes Freitas C, Walsh M, Coutinho EL et al.. “Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial.” PloS one (2021). PMID: 33793580 ↗

    L1RCTCited in: Pharmacokinetics (LADME)
  102. [102]

    Rodríguez-Bernal CL, Santa-Ana-Téllez Y, García-Sempere A et al.. “Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population-based propensity-weighted cohort study.” British journal of clinical pharmacology (2020). PMID: 32530052 ↗

    L2COHORTCited in: Pharmacokinetics (LADME)
  103. [103]

    Sathe AG, Othman AA, Mohamed MF. “Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.” Journal of clinical pharmacology (2020). PMID: 32960975 ↗

    L4SR_OBSCited in: Pharmacokinetics (LADME)
  104. [104]

    Pengo V, Denas G, Zoppellaro G et al.. “Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.” Blood (2018). PMID: 30002145 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  105. [105]

    Raskob G, Ageno W, Cohen AT et al.. “Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.” The Lancet. Haematology (2016). PMID: 27132697 ↗

    L2RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  106. [106]

    Palumbo A, Cavo M, Bringhen S et al.. “Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21282540 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  107. [107]

    Kelly RJ, Hill A, Arnold LM et al.. “Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.” Blood (2011). PMID: 21460245 ↗

    L4TRIAL_NONRANDOMCited in: Pharmacodynamics
  108. [108]

    Sharman JP, Egyed M, Jurczak W et al.. “Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.” Lancet (London, England) (2020). PMID: 32305093 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  109. [109]

    Goette A, Merino JL, Ezekowitz MD et al.. “Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.” Lancet (London, England) (2016). PMID: 27590218 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  110. [110]

    Brekelmans MP, Ageno W, Beenen LF et al.. “Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.” The Lancet. Haematology (2016). PMID: 27570090 ↗

    L2RCTCited in: Pharmacodynamics, Indications and Clinical Use
  111. [111]

    Onundarson PT, Francis CW, Indridason OS et al.. “Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial.” The Lancet. Haematology (2015). PMID: 26688233 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use
  112. [112]

    Boonyawat K, Caron F, Li A et al.. “Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 28407368 ↗

    L1SR_MA_RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose Modification
  113. [113]

    Giugliano RP, Ruff CT, Braunwald E et al.. “Edoxaban versus warfarin in patients with atrial fibrillation.” The New England journal of medicine (2013). PMID: 24251359 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  114. [114]

    Bauersachs R, Berkowitz SD, Brenner B et al.. “Oral rivaroxaban for symptomatic venous thromboembolism.” The New England journal of medicine (2010). PMID: 21128814 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity, Monitoring and Follow-up
  115. [115]

    Agnelli G, Buller HR, Cohen A et al.. “Oral apixaban for the treatment of acute venous thromboembolism.” The New England journal of medicine (2013). PMID: 23808982 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  116. [116]

    Büller HR, Décousus H, Grosso MA et al.. “Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.” The New England journal of medicine (2013). PMID: 23991658 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose and Administration, Adverse Effects and Toxicity
  117. [117]

    Saver JL, Carroll JD, Thaler DE et al.. “Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.” The New England journal of medicine (2017). PMID: 28902590 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  118. [118]

    Cannon CP, Bhatt DL, Oldgren J et al.. “Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.” The New England journal of medicine (2017). PMID: 28844193 ↗

    L1RCTCited in: Pharmacodynamics, Adverse Effects and Toxicity
  119. [119]

    Birnie DH, Healey JS, Wells GA et al.. “Pacemaker or defibrillator surgery without interruption of anticoagulation.” The New England journal of medicine (2013). PMID: 23659733 ↗

    L1RCTCited in: Pharmacodynamics
  120. [120]

    Ruff CT, Giugliano RP, Braunwald E et al.. “Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.” Lancet (London, England) (2013). PMID: 24315724 ↗

    L1SR_OBSCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  121. [121]

    Woller SC, Stevens SM, Kaplan D et al.. “Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial.” Blood advances (2022). PMID: 34662890 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose Modification, Adverse Effects and Toxicity
  122. [122]

    Burbury KL, Milner A, Snooks B et al.. “Short-term warfarin reversal for elective surgery--using low-dose intravenous vitamin K: safe, reliable and convenient*.” British journal of haematology (2011). PMID: 21751986 ↗

    L4TRIAL_NONRANDOMCited in: Pharmacodynamics, Adverse Effects and Toxicity
  123. [123]

    Holmes DR, Reddy VY, Turi ZG et al.. “Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.” Lancet (London, England) (2009). PMID: 19683639 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  124. [124]

    Wallentin L, Yusuf S, Ezekowitz MD et al.. “Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.” Lancet (London, England) (2010). PMID: 20801496 ↗

    L2RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose and Administration, Adverse Effects and Toxicity
  125. [125]

    Lopes RD, Al-Khatib SM, Wallentin L et al.. “Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.” Lancet (London, England) (2012). PMID: 23036896 ↗

    L2RCTCited in: Pharmacodynamics, Indications and Clinical Use
  126. [126]

    Büller HR, Gallus AS, Pillion G et al.. “Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.” Lancet (London, England) (2011). PMID: 22130488 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use
  127. [127]

    Ruff CT, Giugliano RP, Braunwald E et al.. “Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.” Lancet (London, England) (2015). PMID: 25769361 ↗

    L2RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  128. [128]

    Caldeira D, David C, Santos AT et al.. “Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24593838 ↗

    L2SR_OBSCited in: Pharmacodynamics, Indications and Clinical Use
  129. [129]

    Vidal E, Sharathkumar A, Glover J et al.. “Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24801495 ↗

    L2SR_OBSCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity, Special Populations and Contraindications, Monitoring and Follow-up
  130. [130]

    Heit JA, Lahr BD, Petterson TM et al.. “Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study.” Blood (2011). PMID: 21890644 ↗

    L2COHORTCited in: Pharmacodynamics, Dose and Administration, Dose Modification, Special Populations and Contraindications
  131. [131]

    Kampouraki E, Avery PJ, Wynne H et al.. “Assessment of the efficacy of a novel tailored vitamin K dosing regimen in lowering the International Normalised Ratio in over-anticoagulated patients: a randomised clinical trial.” British journal of haematology (2017). PMID: 28771671 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose and Administration, Dose Modification, Adverse Effects and Toxicity
  132. [132]

    Schulman S, Hwang HG, Eikelboom JW et al.. “Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24837794 ↗

    L1RCTCited in: Pharmacodynamics
  133. [133]

    Christersson C, Wallentin L, Andersson U et al.. “D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24942912 ↗

    L2RCTCited in: Pharmacodynamics
  134. [134]

    Hosokawa K, Abe K, Funakoshi K et al.. “Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37044277 ↗

    L2COHORTCited in: Pharmacodynamics
  135. [135]

    Cohen H, Isenberg DA. “How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome.” Blood (2021). PMID: 32898856 ↗

    L5OTHERCited in: Pharmacodynamics
  136. [136]

    Li C, Schwarz UI, Ritchie MD et al.. “Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.” Blood (2008). PMID: 19074728 ↗

    L2OTHERCited in: Pharmacodynamics, Dose and Administration, Dose Modification
  137. [137]

    Moreau C, Bajolle F, Siguret V et al.. “Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement.” Blood (2011). PMID: 22130800 ↗

    L2OTHERCited in: Pharmacodynamics, Dose and Administration, Dose Modification, Special Populations and Contraindications
  138. [138]

    Kushnir M, Choi Y, Eisenberg R et al.. “Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.” The Lancet. Haematology (2019). PMID: 31133411 ↗

    L2OTHERCited in: Pharmacodynamics, Adverse Effects and Toxicity
  139. [139]

    Resende B, Simões M, Ferraz-Costa G et al.. “Meta-Analysis of Randomised Controlled Trials on the Efficacy of Direct Oral Anticoagulants in Left Ventricular Thrombosis: An Updated Perspective.” Heart, lung & circulation (2026). PMID: 42392916 ↗

    L1SR_MA_RCTCited in: Pharmacodynamics
  140. [140]

    Chilaka C, Khan HD, Sarfraz MU et al.. “Left Atrial Appendage Closure vs. Oral Anticoagulation in Patients With Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of arrhythmia (2026). PMID: 42328186 ↗

    L1SR_MA_RCTCited in: Pharmacodynamics
  141. [141]

    Cuttica N, Baumann AN, Yazdanpanah S et al.. “Efficacy of different types of chemoprophylaxis for venous thromboembolism in elective spine surgery: A network meta-analysis of randomized controlled trials.” Journal of orthopaedics (2026). PMID: 41736902 ↗

    L1SR_MA_RCTCited in: Pharmacodynamics
  142. [142]

    Saraei R, Heine GH, Osmancik P et al.. “Left atrial appendage closure in patients with non-valvular atrial fibrillation and end stage chronic KIDNEY disease: Rationale and design of the prospective randomized LAA-KIDNEY trial.” American heart journal (2026). PMID: 42107551 ↗

    L5TRIAL_NONRANDOMCited in: Pharmacodynamics
  143. [143]

    Wu X, Meng J, Yang Y et al.. “Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis.” Renal failure (2026). PMID: 42128628 ↗

    L2SR_OBSCited in: Pharmacodynamics, Adverse Effects and Toxicity
  144. [144]

    Meng M, Xu Q, Qin S et al.. “Efficacy and safety evaluation of thromboprophylaxis strategies for central venous catheter-related thrombosis in cancer patients: a bayesian network meta-analysis and bibliometric analysis.” Frontiers in pharmacology (2026). PMID: 42057843 ↗

    L1SR_OBSCited in: Pharmacodynamics
  145. [145]

    Zhao J, Chen C, Lu L et al.. “NOACs effects in the secondary prevention of atrial fibrillation-related ischemic stroke/TIA: a systematic review and meta-analysis.” Journal of neurology (2026). PMID: 41632318 ↗

    L1SR_OBSCited in: Pharmacodynamics
  146. [146]

    Al Said S, Braunwald E, Palazzolo MG et al.. “Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.” Circulation (2026). PMID: 41614257 ↗

    L1SR_OBSCited in: Pharmacodynamics
  147. [147]

    Li S, Liu S, Liu XR et al.. “Competitive tight-binding inhibition of VKORC1 underlies warfarin dosage variation and antidotal efficacy.” Blood advances (2020). PMID: 32433747 ↗

    L5OTHERCited in: Pharmacodynamics
  148. [148]

    Ingason AB, Hreinsson JP, Agustsson AS et al.. “Comparison of the effectiveness and safety of direct oral anticoagulants: a nationwide propensity score-weighted study.” Blood advances (2023). PMID: 36562754 ↗

    L2OTHERCited in: Pharmacodynamics, Adverse Effects and Toxicity
  149. [149]

    Naymagon L, Tremblay D, Zubizarreta N et al.. “The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis.” Blood advances (2020). PMID: 32078681 ↗

    L2OTHERCited in: Pharmacodynamics
  150. [150]

    Ryu J, La J, Patell R et al.. “Survival assessment of warfarin and international normalized ratio exposure in cancer-associated venous thromboembolism: Veterans Affairs healthcare system-based analysis.” Haematologica (2026). PMID: 41924910 ↗

    L2OTHERCited in: Pharmacodynamics
  151. [151]

    Noble S, Matzdorff A, Maraveyas A et al.. “Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology.” Haematologica (2015). PMID: 26294737 ↗

    L4OTHERCited in: Pharmacodynamics
  152. [152]

    Zhu YF, Qian H, Ma JH et al.. “Effectiveness and Safety of Aspirin Versus Other Antithrombotics for VTE After Total Hip and Knee Arthroplasty in Real-World Setting.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2026). PMID: 41549678 ↗

    L2SR_OBSCited in: Pharmacodynamics
  153. [153]

    Gameil A, Ghasoub R, Jafari N et al.. “Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review.” Oncology (2026). PMID: 41525412 ↗

    L2SR_OBSCited in: Pharmacodynamics
  154. [154]

    Payne JH. “Aspects of anticoagulation in children.” British journal of haematology (2010). PMID: 20528873 ↗

    L5REVIEW_NARRATIVECited in: Pharmacodynamics, Dose and Administration, Adverse Effects and Toxicity, Special Populations and Contraindications, Monitoring and Follow-up
  155. [155]

    Arachchillage DRJ, Alavian S, Griffin J et al.. “Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding.” British journal of haematology (2018). PMID: 30515764 ↗

    L2OTHERCited in: Pharmacodynamics, Adverse Effects and Toxicity
  156. [156]

    Arachchillage DRJ, Laffan M. “What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?” British journal of haematology (2020). PMID: 32108324 ↗

    L5REVIEW_NARRATIVECited in: Pharmacodynamics
  157. [157]

    Czuprynska J, Patel JP, Arya R. “Current challenges and future prospects in oral anticoagulant therapy.” British journal of haematology (2017). PMID: 28573648 ↗

    L5REVIEW_NARRATIVECited in: Pharmacodynamics, Dose and Administration, Dose Modification, Adverse Effects and Toxicity, Monitoring and Follow-up
  158. [158]

    Baker P, Gleghorn A, Tripp T et al.. “Reversal of asymptomatic over-anticoagulation by orally administered vitamin K.” British journal of haematology (2006). PMID: 16643436 ↗

    L5REVIEW_NARRATIVECited in: Pharmacodynamics, Dose and Administration, Dose Modification
  159. [159]

    Chang YC, Song J, Chi KY et al.. “The comparative efficacy and safety of factor Xa inhibitors and warfarin for primary thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy.” British journal of haematology (2024). PMID: 38981737 ↗

    L2OTHERCited in: Pharmacodynamics, Adverse Effects and Toxicity
  160. [160]

    Karthikeyan G, Eikelboom JW, Turpie AG et al.. “Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?” British journal of haematology (2009). PMID: 19438502 ↗

    L5REVIEW_NARRATIVECited in: Pharmacodynamics
  161. [161]

    Costa TA, Felix N, Richter J. “'X' marks the spot! Utilising factor Xa inhibitors to optimise thromboprophylaxis in multiple myeloma.” British journal of haematology (2024). PMID: 38986221 ↗

    L5OTHERCited in: Pharmacodynamics, Adverse Effects and Toxicity
  162. [162]

    Blombäck M, He S, Bark N et al.. “Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate.” British journal of haematology (2011). PMID: 21250974 ↗

    L5OTHERCited in: Pharmacodynamics, Dose and Administration, Dose Modification
  163. [163]

    Montes R, Ruiz de Gaona E, Martínez-González MA et al.. “The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.” British journal of haematology (2006). PMID: 16611310 ↗

    L4OTHERCited in: Pharmacodynamics, Dose and Administration, Dose Modification
  164. [164]

    Cohen H, Efthymiou M, Isenberg DA. “Use of direct oral anticoagulants in antiphospholipid syndrome.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29624847 ↗

    L5REVIEW_NARRATIVECited in: Pharmacodynamics, Adverse Effects and Toxicity
  165. [165]

    Kovac M, Ignjatovic V, Orlando C et al.. “The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39233011 ↗

    L5REVIEW_NARRATIVECited in: Pharmacodynamics, Adverse Effects and Toxicity
  166. [166]

    Rathbun SW, Stoner JA, Whitsett TL. “Treatment of upper-extremity deep vein thrombosis.” Journal of thrombosis and haemostasis : JTH (2011). PMID: 21838756 ↗

    L2OTHERCited in: Pharmacodynamics, Adverse Effects and Toxicity
  167. [167]

    Chao TF, Braunwald E, Palazzolo MG et al.. “Direct oral anticoagulants vs warfarin in Asian vs non-Asian patients with atrial fibrillation: a patient-level meta-analysis from COMBINE AF.” European heart journal (2026). PMID: 42059513 ↗

    L1SR_OBSCited in: Pharmacodynamics
  168. [168]

    Skolnick BE, Mathews DR, Khutoryansky NM et al.. “Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects.” Blood (2010). PMID: 20385794 ↗

    L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  169. [169]

    Lopes RD, Guimarães PO, Kolls BJ et al.. “Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy.” Blood (2017). PMID: 28356246 ↗

    L2RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  170. [170]

    Garcia D, Alexander JH, Wallentin L et al.. “Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures.” Blood (2014). PMID: 25320240 ↗

    L2RCTCited in: Indications and Clinical Use
  171. [171]

    Kearon C, Julian JA, Kovacs MJ et al.. “Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.” Blood (2008). PMID: 18791166 ↗

    L2RCTCited in: Indications and Clinical Use, Dose and Administration, Dose Modification
  172. [172]

    Galli M, Borrelli G, Jacobsen EM et al.. “Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study.” Blood (2007). PMID: 17440049 ↗

    L2RCTCited in: Indications and Clinical Use, Special Populations and Contraindications
  173. [173]

    Sconce E, Avery P, Wynne H et al.. “Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin.” Blood (2006). PMID: 17110451 ↗

    L1RCTCited in: Indications and Clinical Use
  174. [174]

    Cohen H, Hunt BJ, Efthymiou M et al.. “Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.” The Lancet. Haematology (2016). PMID: 27570089 ↗

    L1RCTCited in: Indications and Clinical Use
  175. [175]

    Granger CB, Alexander JH, McMurray JJ et al.. “Apixaban versus warfarin in patients with atrial fibrillation.” The New England journal of medicine (2011). PMID: 21870978 ↗

    L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  176. [176]

    Patel MR, Mahaffey KW, Garg J et al.. “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.” The New England journal of medicine (2011). PMID: 21830957 ↗

    L1RCTCited in: Indications and Clinical Use, Dose Modification, Adverse Effects and Toxicity
  177. [177]

    Calkins H, Willems S, Gerstenfeld EP et al.. “Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.” The New England journal of medicine (2017). PMID: 28317415 ↗

    L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  178. [178]

    Connolly SJ, Ezekowitz MD, Yusuf S et al.. “Dabigatran versus warfarin in patients with atrial fibrillation.” The New England journal of medicine (2009). PMID: 19717844 ↗

    L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  179. [179]

    Douketis JD, Spyropoulos AC, Kaatz S et al.. “Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.” The New England journal of medicine (2015). PMID: 26095867 ↗

    L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  180. [180]

    Eikelboom JW, Connolly SJ, Brueckmann M et al.. “Dabigatran versus warfarin in patients with mechanical heart valves.” The New England journal of medicine (2013). PMID: 23991661 ↗

    L1RCTCited in: Indications and Clinical Use, Dose Modification, Adverse Effects and Toxicity
  181. [181]

    Schulman S, Kearon C, Kakkar AK et al.. “Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.” The New England journal of medicine (2013). PMID: 23425163 ↗

    L1RCTCited in: Indications and Clinical Use, Monitoring and Follow-up
  182. [182]

    Homma S, Thompson JL, Pullicino PM et al.. “Warfarin and aspirin in patients with heart failure and sinus rhythm.” The New England journal of medicine (2012). PMID: 22551105 ↗

    L2RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  183. [183]

    Makkar RR, Fontana G, Jilaihawi H et al.. “Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves.” The New England journal of medicine (2015). PMID: 26436963 ↗

    L4RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  184. [184]

    Starling N, Rao S, Cunningham D et al.. “Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19398575 ↗

    L2RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  185. [185]

    Khorana AA, Kamphuisen PW, Meyer G et al.. “Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 28029329 ↗

    L2RCTCited in: Indications and Clinical Use
  186. [186]

    Ma L, Hu X, Song L et al.. “The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.” Lancet (London, England) (2023). PMID: 37245517 ↗

    L1RCTCited in: Indications and Clinical Use
  187. [187]

    Mant J, Hobbs FD, Fletcher K et al.. “Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.” Lancet (London, England) (2007). PMID: 17693178 ↗

    L1RCTCited in: Indications and Clinical Use
  188. [188]

    Young AM, Billingham LJ, Begum G et al.. “Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial.” Lancet (London, England) (2009). PMID: 19217991 ↗

    L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  189. [189]

    Warkentin AE, Donadini MP, Spencer FA et al.. “Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2012). PMID: 22257078 ↗

    L1SR_MA_RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  190. [190]

    Chai-Adisaksopha C, Hillis C, Isayama T et al.. “Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26356595 ↗

    L1SR_MA_RCTCited in: Indications and Clinical Use
  191. [191]

    Mahé I, Bertrand N, Drouet L et al.. “Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study.” Haematologica (2006). PMID: 17145598 ↗

    L1RCTCited in: Indications and Clinical Use, Drug Interactions
  192. [192]

    Couturaud F, Pernod G, Presles E et al.. “Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial.” Haematologica (2019). PMID: 30606789 ↗

    L1RCTCited in: Indications and Clinical Use, Dose and Administration
  193. [193]

    Asiimwe IG, Blockman M, Cavallari LH et al.. “Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry.” Blood advances (2024). PMID: 39163621 ↗

    L2SR_OBSCited in: Indications and Clinical Use
  194. [194]

    Yoshioka H, Sato H, Hatakeyama H et al.. “Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.” Blood advances (2018). PMID: 29760204 ↗

    L1SR_OBSCited in: Indications and Clinical Use
  195. [195]

    Bradbury C, Fletcher K, Sun Y et al.. “A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study).” British journal of haematology (2019). PMID: 31713863 ↗

    L1RCTCited in: Indications and Clinical Use
  196. [196]

    Gardiner C, Williams K, Longair I et al.. “A randomised control trial of patient self-management of oral anticoagulation compared with patient self-testing.” British journal of haematology (2006). PMID: 16445833 ↗

    L1RCTCited in: Indications and Clinical Use
  197. [197]

    Pengo V, Hoxha A, Andreoli L et al.. “Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 33128325 ↗

    L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  198. [198]

    Poller L, Jespersen J, Ibrahim S. “Warfarin or dabigatran for treatment of atrial fibrillation.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24766817 ↗

    L5RCTCited in: Indications and Clinical Use
  199. [199]

    Kamphuisen PW, Lee AYY, Meyer G et al.. “Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29573330 ↗

    L2RCTCited in: Indications and Clinical Use, Monitoring and Follow-up
  200. [200]

    Ryan F, Byrne S, O'Shea S. “Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system.” Journal of thrombosis and haemostasis : JTH (2009). PMID: 19496921 ↗

    L1RCTCited in: Indications and Clinical Use
  201. [201]

    Heneghan C, Alonso-Coello P, Garcia-Alamino JM et al.. “Self-monitoring of oral anticoagulation: a systematic review and meta-analysis.” Lancet (London, England) (2006). PMID: 16458764 ↗

    L1SR_OBSCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  202. [202]

    Minhas H, Welsher A, Turcotte M et al.. “Incidence of intracranial bleeding in anticoagulated patients with minor head injury: a systematic review and meta-analysis of prospective studies.” British journal of haematology (2018). PMID: 30028001 ↗

    L2SR_OBSCited in: Indications and Clinical Use
  203. [203]

    Saokaew S, Permsuwan U, Chaiyakunapruk N et al.. “Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2010). PMID: 20831620 ↗

    L2SR_OBSCited in: Indications and Clinical Use
  204. [204]

    Wolfe Z, Khan SU, Nasir F et al.. “A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29723935 ↗

    L1SR_OBSCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  205. [205]

    Melkonian M, Jarzebowski W, Pautas E et al.. “Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 28393461 ↗

    L1SR_OBSCited in: Indications and Clinical Use
  206. [206]

    Liew A, O'Donnell M, Douketis J. “Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24986568 ↗

    L1SR_OBSCited in: Indications and Clinical Use
  207. [207]

    Costa TA, Chagas GCL, Tavares de Sousa LM et al.. “Efficacy and safety of direct oral anticoagulants versus warfarin in patients with a left ventricular thrombus: an updated systematic review and meta-analysis of randomised controlled trials.” Open heart (2025). PMID: 41265923 ↗

    L1SR_MA_RCTCited in: Indications and Clinical Use
  208. [208]

    Wang C, Luo J, Zhou X et al.. “Evaluation of a pharmacist-led patient-self-testing model for warfarin management in patients undergoing mechanical heart valve replacement in China: a multicentre, open-label, randomised, controlled trial.” BMJ open (2026). PMID: 41663175 ↗

    L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity, Monitoring and Follow-up
  209. [209]

    Liang M, Jin J, Zhao R et al.. “Dabigatran-based versus warfarin-based triple antithrombotic regimen with a 1-month intensification after coronary stenting in patients with nonvalvular atrial fibrillation (COACH-AF PCI).” BMC medicine (2025). PMID: 41254594 ↗

    L1RCTCited in: Indications and Clinical Use
  210. [210]

    Gao TM, Xiao KQ, Zhou LX et al.. “Comparison of apixaban and warfarin in preventing portal vein system thrombosis after laparoscopic splenectomy for cirrhotic patients with secondary hypersplenism: a randomized controlled trial.” Surgical endoscopy (2025). PMID: 41131381 ↗

    L1RCTCited in: Indications and Clinical Use
  211. [211]

    Ren X, Li Q, Ouyang M et al.. “Mediation Analysis to Identify Individual Component Effects of the Care Bundle to Improve Functional Outcome After ICH in the INTERACT3 Study.” Neurology (2025). PMID: 40939125 ↗

    L1RCTCited in: Indications and Clinical Use
  212. [212]

    Mehta A, Bagchi P, Looby M et al.. “Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2025). PMID: 40819750 ↗

    L1RCTCited in: Indications and Clinical Use, Dose Modification
  213. [213]

    Nicolau AM, Giugliano RP, Zimerman A et al.. “Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF Substudy.” Journal of the American College of Cardiology (2025). PMID: 40769671 ↗

    L1RCTCited in: Indications and Clinical Use
  214. [214]

    Stone P, Minton O, Richardson A et al.. “Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial.” Health technology assessment (Winchester, England) (2025). PMID: 40755226 ↗

    L1RCTCited in: Indications and Clinical Use
  215. [215]

    Moonsamy P, Zhao Y, Makarem A et al.. “Randomized Controlled: Trial of New Oral Anticoagulants Versus Warfarin for Postcardiac Surgery Atrial Fibrillation: The NEW-AF Trial.” Annals of surgery (2025). PMID: 40704706 ↗

    L1RCTCited in: Indications and Clinical Use
  216. [216]

    Izumi C, Amano M, Yoshikawa Y et al.. “Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: A Randomized Clinical Trial.” Circulation. Cardiovascular interventions (2025). PMID: 40663622 ↗

    L1RCTCited in: Indications and Clinical Use
  217. [217]

    Parker WAE, Nelson TA, Lee J et al.. “Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial.” European heart journal (2026). PMID: 40444814 ↗

    L2RCTCited in: Indications and Clinical Use
  218. [218]

    Qian Y, Chen W, Zhou B et al.. “Efficacy, Safety, and Cost-Effectiveness of "Internet + Pharmacy Care" Via the Alfalfa App in Warfarin Therapy Management After Cardiac Valve Replacement: Randomized Controlled Trial.” JMIR mHealth and uHealth (2025). PMID: 40393057 ↗

    L1RCTCited in: Indications and Clinical Use, Dose Modification
  219. [219]

    Dangas GD, Unverdorben M, Nicolas J et al.. “Comparing Major Gastrointestinal Bleeding in Patients Receiving Edoxaban Versus Warfarin After Transcatheter Aortic Valve Replacement: Results From the Randomized ENVISAGE-TAVI AF Trial.” Journal of the American Heart Association (2025). PMID: 40371611 ↗

    L1RCTCited in: Indications and Clinical Use, Dose Modification
  220. [220]

    Kurlander JE, Helminski D, Tao X et al.. “An Intervention to Reduce Antiplatelet Use without Gastroprotection in Patients Using Warfarin: The AEGIS Cluster Randomized Trial.” Thrombosis and haemostasis (2025). PMID: 40315868 ↗

    L1RCTCited in: Indications and Clinical Use
  221. [221]

    Chairat P, Niprapan P, Hantrakun N et al.. “Randomized controlled trial evaluating the benefit of the app-based clinical decision support system for the management of venous thromboembolism.” BMC medical education (2025). PMID: 40159474 ↗

    L1RCTCited in: Indications and Clinical Use
  222. [222]

    Semco RS, Bergmark RW, Murphy SA et al.. “Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial.” Journal of the American Heart Association (2025). PMID: 39791401 ↗

    L1RCTCited in: Indications and Clinical Use
  223. [223]

    Ruel M, Chu MWA, Graeve A et al.. “Midterm survival, clinical, and hemodynamic outcomes of a novel mechanical mitral valve prosthesis.” The Journal of thoracic and cardiovascular surgery (2024). PMID: 39617318 ↗

    L1RCTCited in: Indications and Clinical Use
  224. [224]

    Lip GY, Halperin JL, Petersen P et al.. “A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26052866 ↗

    L1RCTCited in: Dose and Administration
  225. [225]

    Shrivastava S, Ridker PM, Glynn RJ et al.. “D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism.” Journal of thrombosis and haemostasis : JTH (2006). PMID: 16706961 ↗

    L1RCTCited in: Dose and Administration
  226. [226]

    Buller HR, Halperin J, Hankey GJ et al.. “Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24597472 ↗

    L1RCTCited in: Dose and Administration, Dose Modification
  227. [227]

    Lassen MR, Davidson BL, Gallus A et al.. “The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.” Journal of thrombosis and haemostasis : JTH (2007). PMID: 17868430 ↗

    L1RCTCited in: Dose and Administration, Dose Modification
  228. [228]

    Raskob G, Büller H, Prins M et al.. “Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.” Journal of thrombosis and haemostasis : JTH (2013). PMID: 23574579 ↗

    L5RCTCited in: Dose and Administration
  229. [229]

    Lund K, Gaffney D, Spooner R et al.. “Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.” British journal of haematology (2012). PMID: 22571356 ↗

    L2TRIAL_NONRANDOMCited in: Dose and Administration, Adverse Effects and Toxicity, Monitoring and Follow-up
  230. [230]

    Holm J, Lindh JD, Andersson ML et al.. “The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 28058824 ↗

    L3COHORTCited in: Dose and Administration, Dose Modification, Monitoring and Follow-up
  231. [231]

    Mannheimer B, Andersson ML, Järnbert-Pettersson H et al.. “The effect of carbamazepine on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population.” Journal of thrombosis and haemostasis : JTH (2016). PMID: 26792124 ↗

    L3COHORTCited in: Dose and Administration, Drug Interactions
  232. [232]

    Ruell J, Smith A, Perera T et al.. “The role of a specialist bridging service. A New Zealand prospective study of 600 patients.” Journal of thrombosis and haemostasis : JTH (2019). PMID: 31215756 ↗

    L4COHORTCited in: Dose and Administration, Special Populations and Contraindications
  233. [233]

    Zimerman A, Braunwald E, Steffel J et al.. “Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.” JAMA cardiology (2024). PMID: 38985461 ↗

    L2RCTCited in: Dose and Administration, Dose Modification
  234. [234]

    Shu L, Jack N, de Havenon A et al.. “Risk factors for MACE and bleeding in atrial fibrillation patients undergoing surgery: Insights from the bridge trial.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2024). PMID: 38944363 ↗

    L2RCTCited in: Dose and Administration
  235. [235]

    Xue L, Ma G, Holford N et al.. “A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization.” Clinical pharmacology and therapeutics (2024). PMID: 38439157 ↗

    L1RCTCited in: Dose and Administration, Dose Modification, Monitoring and Follow-up
  236. [236]

    Steffel J, Ruff CT, Yin O et al.. “Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.” Journal of the American College of Cardiology (2021). PMID: 33663737 ↗

    L1RCTCited in: Dose and Administration
  237. [237]

    Wilkinson C, Wu J, Searle SD et al.. “Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial.” BMC medicine (2020). PMID: 33357217 ↗

    L2RCTCited in: Dose and Administration
  238. [238]

    Biss TT, Avery PJ, Brandão LR et al.. “VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.” Blood (2011). PMID: 22010099 ↗

    L4OTHERCited in: Dose and Administration, Dose Modification, Special Populations and Contraindications
  239. [239]

    Zhang RF, Ma CM, Wang N et al.. “Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment.” BMC cardiovascular disorders (2021). PMID: 33906609 ↗

    L2RCTCited in: Dose and Administration
  240. [240]

    Zhang H, Li M, Ao XL et al.. “Randomized, placebo-controlled trial of orally administered vitamin K1 for warfarin-associated coagulopathy in Chinese patients with mechanical heart valves.” European journal of clinical pharmacology (2021). PMID: 33783553 ↗

    L1RCTCited in: Dose and Administration
  241. [241]

    Ning X, Kuang Y, Yang G et al.. “Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial.” Naunyn-Schmiedeberg's archives of pharmacology (2021). PMID: 33404689 ↗

    L2RCTCited in: Dose and Administration
  242. [242]

    Suwanawiboon B, Rotchanapanya W, Mahaprom K et al.. “The efficacy of low-dose warfarin initiation (3 mg versus 5 mg) in newly diagnosed venous thromboembolism patients among a population with a high prevalence of warfarin-sensitive haplotype of the VKORC1 gene: a randomized controlled trial.” Hematology (Amsterdam, Netherlands) (2022). PMID: 35068386 ↗

    L1RCTCited in: Dose and Administration
  243. [243]

    Toomey JR, Abboud MA, Valocik RE et al.. “A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis.” Journal of thrombosis and haemostasis : JTH (2006). PMID: 16961606 ↗

    L5OTHERCited in: Dose and Administration, Dose Modification
  244. [244]

    Le Gal G, Carrier M, Tierney S et al.. “Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping?” Journal of thrombosis and haemostasis : JTH (2009). PMID: 19874475 ↗

    L3OTHERCited in: Dose and Administration
  245. [245]

    Hurtado FK, de Braud F, De Castro Carpeño J et al.. “Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors.” Cancer chemotherapy and pharmacology (2021). PMID: 33394101 ↗

    L4TRIAL_NONRANDOMCited in: Dose and Administration
  246. [246]

    El Rouby N, Shahin MH, Bader L et al.. “Genomewide association analysis of warfarin dose requirements in Middle Eastern and North African populations.” Clinical and translational science (2021). PMID: 34729928 ↗

    L4SR_OBSCited in: Dose and Administration
  247. [247]

    Huang W, Sun H, Zhou L et al.. “Application of Loading Dose Warfarin in Postpartum Women with Pulmonary Embolism - a Prospective, Randomized, Double-Blind Trial.” Drug design, development and therapy (2025). PMID: 41321667 ↗

    L1RCTCited in: Dose and Administration
  248. [248]

    Menon N, Sarode R, Zia A. “Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis.” Blood advances (2018). PMID: 29365322 ↗

    L4CASE_REPORTCited in: Dose Modification, Adverse Effects and Toxicity
  249. [249]

    Ortel TL. “Perioperative management of patients on chronic antithrombotic therapy.” Blood (2012). PMID: 22855600 ↗

    L5REVIEW_NARRATIVECited in: Dose Modification, Adverse Effects and Toxicity
  250. [250]

    Zhou Q, Wang Z, Wang H et al.. “Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2023). PMID: 36622539 ↗

    L4TRIAL_NONRANDOMCited in: Dose Modification
  251. [251]

    Pilc E, Bankuru SV, Brauer SF et al.. “Which Interventions Are Effective in Treating Sleep Disturbances After THA or TKA? A Systematic Review.” Clinical orthopaedics and related research (2024). PMID: 39255465 ↗

    L5SR_OBSCited in: Dose Modification
  252. [252]

    Yang Z, Wang J, Yuan Y et al.. “Application of rivaroxaban in patients with non-valvular atrial fibrillation and end-stage kidney disease: A systematic review and meta-analysis.” Frontiers in cardiovascular medicine (2023). PMID: 36844734 ↗

    L1SR_OBSCited in: Dose Modification
  253. [253]

    Tham D, Zhao L, Yu W et al.. “Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis.” Research and practice in thrombosis and haemostasis (2024). PMID: 39568775 ↗

    L2SR_OBSCited in: Dose Modification
  254. [254]

    Larsen TB, Skjøth F, Kjældgaard JN et al.. “Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.” The Lancet. Haematology (2017). PMID: 28411120 ↗

    L2COHORTCited in: Adverse Effects and Toxicity
  255. [255]

    Bouillon K, Bertrand M, Maura G et al.. “Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.” The Lancet. Haematology (2015). PMID: 26687957 ↗

    L2COHORTCited in: Adverse Effects and Toxicity
  256. [256]

    Keeling D, Davidson S, Watson H. “The management of heparin-induced thrombocytopenia.” British journal of haematology (2006). PMID: 16643427 ↗

    L1GUIDELINECited in: Adverse Effects and Toxicity
  257. [257]

    Afzal A, Gage BF, Suhong L et al.. “Different risks of hemorrhage in patients with elevated international normalized ratio from chronic liver disease versus warfarin therapy, a population-based retrospective cohort study.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35491428 ↗

    L2COHORTCited in: Adverse Effects and Toxicity
  258. [258]

    Green L, Tan J, Morris JK et al.. “A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study).” Haematologica (2018). PMID: 29371325 ↗

    L2TRIAL_NONRANDOMCited in: Adverse Effects and Toxicity
  259. [259]

    Gailani D, Gruber A. “Targeting factor XI and factor XIa to prevent thrombosis.” Blood (2024). PMID: 38142404 ↗

    L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity, Monitoring and Follow-up
  260. [260]

    Schmidt RA, Lee AYY. “How I treat and prevent venous thrombotic complications in patients with lymphoma.” Blood (2022). PMID: 34479364 ↗

    L5OTHERCited in: Adverse Effects and Toxicity
  261. [261]

    Chan NC, Eikelboom JW. “How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism.” Blood (2019). PMID: 30926593 ↗

    L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
  262. [262]

    Goodnough LT, Shander A. “How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage.” Blood (2011). PMID: 21411756 ↗

    L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
  263. [263]

    Khorana AA. “The wacky hypercoagulable state of malignancy.” Blood (2015). PMID: 26206943 ↗

    L5OTHERCited in: Adverse Effects and Toxicity
  264. [264]

    Chen X, Li C, Jin DY et al.. “A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle.” Blood (2020). PMID: 32374827 ↗

    L5OTHERCited in: Adverse Effects and Toxicity
  265. [265]

    Oskarsdottir AR, Gudmundsdottir BR, Jensdottir HM et al.. “Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.” Blood (2021). PMID: 33512454 ↗

    L2OTHERCited in: Adverse Effects and Toxicity, Monitoring and Follow-up
  266. [266]

    Quintás-Cardama A, Han X, Kantarjian H et al.. “Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.” Blood (2009). PMID: 19414863 ↗

    L4OTHERCited in: Adverse Effects and Toxicity
  267. [267]

    Zhang H, Löwenberg EC, Crosby JR et al.. “Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.” Blood (2010). PMID: 20807891 ↗

    L5OTHERCited in: Adverse Effects and Toxicity
  268. [268]

    Kelkar AH, Smith NA, Martial A et al.. “An Outbreak of Synthetic Cannabinoid-Associated Coagulopathy in Illinois.” The New England journal of medicine (2018). PMID: 30280655 ↗

    L4OTHERCited in: Adverse Effects and Toxicity
  269. [269]

    Bell C, Afzal A, Carlin S et al.. “Prevention and treatment of thrombosis in patients with decompensated cirrhosis.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41520803 ↗

    L5CASE_REPORTCited in: Adverse Effects and Toxicity
  270. [270]

    Sakusic A, Ghozy S, Verma Y et al.. “Resumption of Warfarin After Intracranial Hemorrhage in Patients With Mechanical Heart Valves: A Systematic Review and Meta-Analysis.” Journal of the American Heart Association (2026). PMID: 41823243 ↗

    L2SR_OBSCited in: Adverse Effects and Toxicity
  271. [271]

    Paquette M, Miranda S, Xu Y et al.. “Perioperative management of antithrombotic therapy in patients with thrombotic antiphospholipid syndrome.” Blood advances (2026). PMID: 41843780 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  272. [272]

    Ma S, Chang YC, Chiang CH et al.. “Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism.” Blood advances (2026). PMID: 40845270 ↗

    L2OTHERCited in: Adverse Effects and Toxicity, Monitoring and Follow-up
  273. [273]

    Weycker D, Wygant GD, Guo JD et al.. “Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses.” Blood advances (2020). PMID: 31990332 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  274. [274]

    Dawwas GK, Cuker A, Lewis JD. “Bleeding and thrombotic outcomes with oral anticoagulants in patients with inflammatory bowel disease and venous thromboembolism.” Blood advances (2026). PMID: 41191527 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  275. [275]

    Shah S, Norby FL, Datta YH et al.. “Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.” Blood advances (2018). PMID: 29378726 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  276. [276]

    Hanni C, Petrovitch E, Ali M et al.. “Outcomes associated with apixaban vs warfarin in patients with renal dysfunction.” Blood advances (2020). PMID: 32463871 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  277. [277]

    Dawwas GK, Cuker A, Schaubel DE et al.. “Effectiveness and safety of prophylactic anticoagulation among hospitalized patients with inflammatory bowel disease.” Blood advances (2024). PMID: 38163322 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  278. [278]

    Leader A, Hamulyák EN, Carney BJ et al.. “Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases.” Blood advances (2020). PMID: 33351124 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  279. [279]

    Alomairi AA, Alduhaysh R, Samandar A et al.. “Cerebrovascular and Bleeding Outcomes of Warfarin versus Direct Oral Anticoagulants Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Neurosciences (Riyadh, Saudi Arabia) (2026). PMID: 42415975 ↗

    L1SR_MA_RCTCited in: Adverse Effects and Toxicity
  280. [280]

    Lip GY, Tse HF, Lane DA. “Atrial fibrillation.” Lancet (London, England) (2011). PMID: 22166900 ↗

    L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
  281. [281]

    Chakravarty T, Søndergaard L, Friedman J et al.. “Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study.” Lancet (London, England) (2017). PMID: 28330690 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  282. [282]

    Zwicker JI, Paranagama D, Lessen DS et al.. “Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study.” Haematologica (2022). PMID: 34162181 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  283. [283]

    Krauth MT, Lechner K, Neugebauer EA et al.. “The postoperative splenic/portal vein thrombosis after splenectomy and its prevention--an unresolved issue.” Haematologica (2008). PMID: 18556406 ↗

    L5OTHERCited in: Adverse Effects and Toxicity
  284. [284]

    Liu E, Tilbury N, Morin T et al.. “Antiplatelet and Anticoagulation Use and Outcomes Following Chronic Subdural Hematoma Drainage: Systematic Review and Meta-analysis.” World neurosurgery (2026). PMID: 41707892 ↗

    L1SR_OBSCited in: Adverse Effects and Toxicity
  285. [285]

    Scully M, Gates C, Neave L. “How we manage patients with heparin induced thrombocytopenia.” British journal of haematology (2016). PMID: 27097741 ↗

    L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
  286. [286]

    Parker K, Mitra S, Thachil J. “Is anticoagulating haemodialysis patients with non-valvular atrial fibrillation too risky?” British journal of haematology (2018). PMID: 29468649 ↗

    L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
  287. [287]

    Pastori D, Lip GYH, Poli D et al.. “Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study.” British journal of haematology (2020). PMID: 32080833 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  288. [288]

    Wheeler DS, Giugliano RP, Rangaswami J. “Anticoagulation-related nephropathy.” Journal of thrombosis and haemostasis : JTH (2016). PMID: 26670286 ↗

    L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
  289. [289]

    Dawwas GK, Cuker A. “Comparative effectiveness and safety of rivaroxaban with other oral anticoagulants in older adults with nonvalvular atrial fibrillation: population-based analysis in response to updated Beers Criteria.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39442621 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  290. [290]

    Lee J, Kong X, Haymart B et al.. “Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35962753 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  291. [291]

    Youssef E, Daher M, Milad A et al.. “Is dabigatran a good alternative to warfarin in patients with atrial fibrillation accompanied by valvular and non-valvular heart diseases? A systematic review and meta-analysis.” La Tunisie medicale (2025). PMID: 41879686 ↗

    L1SR_OBSCited in: Adverse Effects and Toxicity
  292. [292]

    Tuo M, Li Y, Shi Z et al.. “Case Report: Recurrent coronary in-stent restenosis as the primary manifestation of non-criteria antiphospholipid syndrome confirmed by anti-phosphatidylserine/prothrombin IgM antibodies.” Frontiers in immunology (2026). PMID: 42358967 ↗

    L4CASE_REPORTCited in: Adverse Effects and Toxicity
  293. [293]

    Kim D, Jo S, Hwang I et al.. “Association of anticoagulant and antiplatelet therapy with acute cerebral infarction in patients presenting with isolated vertigo or dizziness: A retrospective cohort study.” PloS one (2026). PMID: 42275463 ↗

    L2COHORTCited in: Adverse Effects and Toxicity
  294. [294]

    Theivendran T, Vucak-Dzumhur M, Lee VW et al.. “Topical Sodium Thiosulfate for the Treatment of Calciphylaxis: Case Report.” Nephrology (Carlton, Vic.) (2026). PMID: 42104624 ↗

    L4CASE_REPORTCited in: Adverse Effects and Toxicity
  295. [295]

    Menichelli D, Cormaci VMD, Gazzaniga G et al.. “Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality.” Cancer (2026). PMID: 42411384 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  296. [296]

    Crowley B, Hollimon M, Joaquin T et al.. “The Impact of Anticoagulant Choice on Rates of Manipulation Under Anesthesia, Hematoma Formation, and Venous Thromboembolic Events.” The Journal of arthroplasty (2026). PMID: 42373147 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  297. [297]

    Shoji S, Gouda P, Falvey CA et al.. “Patient-Centered Evaluation of Anticoagulation in Atrial Fibrillation.” NEJM evidence (2026). PMID: 42187550 ↗

    L1OTHERCited in: Adverse Effects and Toxicity
  298. [298]

    Anan K, Itaya T, Kataoka Y et al.. “Direct Oral Anticoagulant Consumption and the Risk of Acute Interstitial Lung Diseases: A Case-Crossover Study Using Japanese Administrative Data.” Pharmacoepidemiology and drug safety (2026). PMID: 42175652 ↗

    L3OTHERCited in: Adverse Effects and Toxicity
  299. [299]

    Gouda P, Harrington J, Arps K et al.. “Predictors of ischemic stroke and major bleeding among patients with atrial fibrillation in clinical practice.” American heart journal (2026). PMID: 42162604 ↗

    L2OTHERCited in: Adverse Effects and Toxicity
  300. [300]

    Kategeaw W, Witt DM, King JB et al.. “Cost-Effectiveness Analysis of Patient Self-Management of Warfarin Among Patients With Non-Valvular Atrial Fibrillation.” Pharmacotherapy (2026). PMID: 42136139 ↗

    L5OTHERCited in: Adverse Effects and Toxicity
  301. [301]

    Vazquez SR. “Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.” Blood (2018). PMID: 30463993 ↗

    L5REVIEW_NARRATIVECited in: Drug Interactions
  302. [302]

    Verheugt FW, Granger CB. “Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.” Lancet (London, England) (2015). PMID: 25777666 ↗

    L5REVIEW_NARRATIVECited in: Drug Interactions
  303. [303]

    Galliazzo S, Bucciarelli P, Barcellona D et al.. “Practical Suggestions for an Optimal Management of Vitamin K Antagonists: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper.” Thrombosis and haemostasis (2024). PMID: 38626900 ↗

    L5GUIDELINECited in: Drug Interactions, Monitoring and Follow-up
  304. [304]

    Cabral KP, Ansell J, Hylek EM. “Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification.” Journal of thrombosis and haemostasis : JTH (2011). PMID: 21176102 ↗

    L5REVIEW_NARRATIVECited in: Drug Interactions
  305. [305]

    Nguyen AT, Tepper NK, Gold H et al.. “Safety of contraception among women using anticoagulant therapy: An updated systematic review.” Contraception (2025). PMID: 41177211 ↗

    L2SR_OBSCited in: Drug Interactions
  306. [306]

    Ho JJY, Goh C, Leong CSA et al.. “Evaluation of potential drug-drug interactions with medical cannabis.” Clinical and translational science (2024). PMID: 38720531 ↗

    L2SR_OBSCited in: Drug Interactions
  307. [307]

    Calvarysky B, Dotan I, Shepshelovich D et al.. “Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review.” Drug safety (2024). PMID: 38273155 ↗

    L1SR_OBSCited in: Drug Interactions
  308. [308]

    Smythe MA, Wu W, Garwood CL. “Anticoagulant drug-drug interactions with cannabinoids: A systematic review.” Pharmacotherapy (2023). PMID: 37740600 ↗

    L2SR_OBSCited in: Drug Interactions
  309. [309]

    Hughes JE, Waldron C, Bennett KE et al.. “Prevalence of Drug-Drug Interactions in Older Community-Dwelling Individuals: A Systematic Review and Meta-analysis.” Drugs & aging (2023). PMID: 36692678 ↗

    L1SR_OBSCited in: Drug Interactions
  310. [310]

    Iversen DB, Dunvald AD, Jespersen DM et al.. “Flucloxacillin Is a Weak Inducer of CYP3A4 in Healthy Adults and 3D Spheroid of Primary Human Hepatocytes.” Clinical pharmacology and therapeutics (2023). PMID: 37235733 ↗

    L1RCTCited in: Drug Interactions
  311. [311]

    Wood MD, Delate T, Clark M et al.. “An evaluation of the potential drug interaction between warfarin and levothyroxine.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24913218 ↗

    L3OTHERCited in: Drug Interactions
  312. [312]

    Smith SA, Morrissey JH. “Polyphosphate as a general procoagulant agent.” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18665922 ↗

    L5OTHERCited in: Drug Interactions
  313. [313]

    Wijnen JC, van de Riet IR, Lijfering WM et al.. “Metformin use decreases the anticoagulant effect of phenprocoumon.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24698366 ↗

    L3OTHERCited in: Drug Interactions
  314. [314]

    Stage TB, Pottegård A, Henriksen DP et al.. “Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26559049 ↗

    L3OTHERCited in: Drug Interactions
  315. [315]

    Bérété ZC, Sebgo AA, Eurich DT et al.. “Concomitant use of medical cannabis and drugs associated with risks of interaction in older patients: a longitudinal cohort study.” Age and ageing (2025). PMID: 41396801 ↗

    L2COHORTCited in: Drug Interactions
  316. [316]

    Witmer C, Raffini L. “Treatment of venous thromboembolism in pediatric patients.” Blood (2020). PMID: 31917400 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Contraindications
  317. [317]

    Kamat AV, D'Cruz DP, Hunt BJ. “Managing antiphospholipid antibodies and antiphospholipid syndrome in children.” Haematologica (2006). PMID: 17145604 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Contraindications
  318. [318]

    Arachchillage DRJ, Laffan M. “Pathogenesis and management of antiphospholipid syndrome.” British journal of haematology (2017). PMID: 28339096 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Contraindications
  319. [319]

    Cohen H, Efthymiou M, Devreese KMJ. “Monitoring of anticoagulation in thrombotic antiphospholipid syndrome.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 33325604 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Contraindications
  320. [320]

    Nowak-Göttl U, Dietrich K, Schaffranek D et al.. “In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.” Blood (2010). PMID: 20833980 ↗

    L2OTHERCited in: Special Populations and Contraindications
  321. [321]

    Li HY, Wang J, Wang T et al.. “Management of venous thromboembolism in pediatric patients: Quality assessment of clinical practice guidelines and variations in recommendations.” Thrombosis research (2023). PMID: 37141795 ↗

    L5GUIDELINECited in: Special Populations and Contraindications
  322. [322]

    Furlan A, Vianello F, Clementi M et al.. “Heparin- induced thrombocytopenia occurring in the first trimester of pregnancy: successful treatment with lepirudin. A case report.” Haematologica (2006). PMID: 16923524 ↗

    L4CASE_REPORTCited in: Special Populations and Contraindications
  323. [323]

    Iancu A, Leb I, Prokosch HU et al.. “Machine learning in medication prescription: A systematic review.” International journal of medical informatics (2023). PMID: 37939541 ↗

    L2SR_OBSCited in: Special Populations and Contraindications
  324. [324]

    Shishesaz MI, Eshraghi R, Bahrami A et al.. “The effectiveness and side effects of anti-coagulant drugs in pregnant women with mechanical or bio-prosthetic heart valves: A systematic review and meta-analysis study.” Journal of cardiology (2025). PMID: 40816699 ↗

    L1SR_OBSCited in: Special Populations and Contraindications
  325. [325]

    Assempoor R, Abroy AS, Azarboo A et al.. “Different antithrombotic strategies to prevent cardiovascular complications in Kawasaki patients: a systematic review and meta-analysis.” BMC pediatrics (2024). PMID: 39548432 ↗

    L1SR_OBSCited in: Special Populations and Contraindications
  326. [326]

    Zhang Z, Zhou J, Lin Q et al.. “Overcoming barriers for left atrial appendage thrombus: a systematic review of left atrial appendage closure.” BMC cardiovascular disorders (2024). PMID: 38515032 ↗

    L2SR_OBSCited in: Special Populations and Contraindications
  327. [327]

    DeSancho MT, Suvar E, Roberts JC et al.. “Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39151704 ↗

    L2OTHERCited in: Special Populations and Contraindications
  328. [328]

    Neuman YP, Sawaid K, Cohen O et al.. “Age-Specific Differences in Cerebral Sinus Venous Thrombosis: A Retrospective Cohort Study From a Tertiary Care Center.” Pediatric blood & cancer (2025). PMID: 40734251 ↗

    L2COHORTCited in: Special Populations and Contraindications
  329. [329]

    Tan H, Zhang X, Wang W et al.. “Percutaneous Transluminal Angioplasty Alleviate Pediatric Postthrombotic Syndrome: A Case Report and Literature Review.” Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2024). PMID: 39086107 ↗

    L4CASE_REPORTCited in: Special Populations and Contraindications
  330. [330]

    Federspiel JJ, Rodger MA, Hoffman MR et al.. “Postoperative venous thromboembolism following cesarean delivery: prevalence, pathophysiology, diagnosis, treatment, and prevention.” American journal of obstetrics and gynecology (2026). PMID: 41485833 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Contraindications
  331. [331]

    Mittal P, Sayar Z, Cohen H. “Warfarin and heparin monitoring in antiphospholipid syndrome.” Hematology. American Society of Hematology. Education Program (2024). PMID: 39644000 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Contraindications, Monitoring and Follow-up
  332. [332]

    Schulman S, Kearon C, Kakkar AK et al.. “Dabigatran versus warfarin in the treatment of acute venous thromboembolism.” The New England journal of medicine (2009). PMID: 19966341 ↗

    L1RCTCited in: Monitoring and Follow-up
  333. [333]

    Matchar DB, Jacobson A, Dolor R et al.. “Effect of home testing of international normalized ratio on clinical events.” The New England journal of medicine (2010). PMID: 20961244 ↗

    L1RCTCited in: Monitoring and Follow-up
  334. [334]

    Jonsson PI, Letertre L, Juliusson SJ et al.. “During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time.” Journal of thrombosis and haemostasis : JTH (2016). PMID: 27774726 ↗

    L2RCTCited in: Monitoring and Follow-up
  335. [335]

    Ferder NS, Eby CS, Deych E et al.. “Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.” Journal of thrombosis and haemostasis : JTH (2009). PMID: 19874474 ↗

    L2RCTCited in: Monitoring and Follow-up
  336. [336]

    Witt DM, Delate T, Clark NP et al.. “Outcomes and predictors of very stable INR control during chronic anticoagulation therapy.” Blood (2009). PMID: 19439733 ↗

    L2OTHERCited in: Monitoring and Follow-up
  337. [337]

    Budnitz DS, Lovegrove MC, Shehab N et al.. “Emergency hospitalizations for adverse drug events in older Americans.” The New England journal of medicine (2011). PMID: 22111719 ↗

    L2OTHERCited in: Monitoring and Follow-up
  338. [338]

    Kontopodis N, Galanakis N, Ioannou CV et al.. “Systematic Review and Meta-Analysis of the Effect of Anticoagulation on Outcomes After Endovascular Aneurysm Repair.” Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2023). PMID: 38031419 ↗

    L2SR_OBSCited in: Monitoring and Follow-up
  339. [339]

    Gopalakrishnan C, Schneeweiss S, Bartels DB et al.. “Evaluating utilization patterns of oral anticoagulants in routine care.” Journal of thrombosis and haemostasis : JTH (2019). PMID: 31038824 ↗

    L2OTHERCited in: Monitoring and Follow-up
  340. [340]

    Chiasakul T, Redd R, Patell R et al.. “Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34490999 ↗

    L2OTHERCited in: Monitoring and Follow-up
  341. [341]

    Mao T, Xia X, Ma R. “Pharmacist-Led Genotype-Guided Warfarin Therapy in Valve Replacement: An Observation Cohort Study.” The Journal of surgical research (2025). PMID: 40816100 ↗

    L2COHORTCited in: Monitoring and Follow-up
  342. [342]

    Namjouyan K, Hassan Virk HU, Rizwan A et al.. “Left atrial appendage closure devices: a contemporary review of techniques, tips and tricks.” Frontiers in cardiovascular medicine (2026). PMID: 42064858 ↗

    L5REVIEW_NARRATIVECited in: Monitoring and Follow-up

Revision History

All updates applied to this page

Loading revisions…